Publications by authors named "Jessica L Buono"
Background: The economic burden associated with irritable bowel syndrome with diarrhea (IBS-D) is not well understood.
Objectives: To (a) evaluate total annual all-cause, gastrointestinal (GI)-related, and symptom-related (i.e.
Article Synopsis
- Irritable bowel syndrome with diarrhea (IBS-D) affects 10-15% of adults in the US and significantly reduces their health-related quality of life (HRQoL), work productivity, and daily activities, but there's a lack of specific data about this subtype.
- A study analyzed data from 66,491 respondents, showing that those with IBS-D had notably lower mental and physical health scores compared to controls, as well as higher rates of absenteeism and presenteeism.
- The results suggest that IBS-D not only impacts personal health but also leads to increased indirect costs due to productivity losses at work and diminishes overall quality of life.
Aims: To assess healthcare resource use and costs among irritable bowel syndrome (IBS) with diarrhea (IBS-D) patients with and without evidence of inadequate symptom control on current prescription therapies and estimate incremental all-cause costs associated with inadequate symptom control.
Methods: IBS-D patients aged ≥18 years with ≥1 medical claim for IBS (ICD-9-CM 564.1x) and either ≥2 claims for diarrhea (ICD-9-CM 787.
Article Synopsis
- Irritable bowel syndrome with constipation (IBS-C) is a chronic condition that impacts both work productivity and daily life, creating challenges for patients and employers.
- Linaclotide, a medication approved for IBS-C, was studied for its effects on work and activity impairment through two phase 3 clinical trials.
- Results indicated that linaclotide significantly improved work productivity and reduced daily activity limitations in patients with IBS-C, showing a notable decrease in presenteeism and overall productivity loss compared to a placebo.
Article Synopsis
- - The study examines the prevalence and associated health care costs of irritable bowel syndrome with constipation (IBS-C), affecting 4.3% to 5.2% of U.S. adults, aiming to assess total costs in individuals seeking medical care and compare these costs to matched controls.
- - Researchers utilized a large database to identify IBS-C patients and controls, ensuring accurate comparison by matching on age, gender, and health plan characteristics, while excluding those with certain other diagnoses.
- - Findings were focused on calculating annual health care costs related to IBS-C, including expenses from various medical services and prescriptions, providing insight into the financial impact of this condition.
Objective: To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls.
Methods: Patients aged ≥18 years with continuous medical and pharmacy benefit eligibility in 2010 were identified from the HealthCore Integrated Research Database. CC patients had ≥2 medical claims for constipation (ICD-9-CM code 564.
Purpose: Rate and rhythm control are two well established treatment objectives for atrial fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic practice related to cardioversion varies by region and patient, with several precautions associated with the use of current therapies. No comprehensive literature review on the relative efficacy of existing cardioversion approaches compared to newly available therapies has been conducted.
View Article and Find Full Text PDF